[go: up one dir, main page]

AR018135A1 - Vacuna viva recombinante, utilizacion de un compuesto elegido entre los polimeros del acido acrilico o metacrilico y los copolimeros de ahidrido maleico yde derivado alquenilo y kit de vacunacion - Google Patents

Vacuna viva recombinante, utilizacion de un compuesto elegido entre los polimeros del acido acrilico o metacrilico y los copolimeros de ahidrido maleico yde derivado alquenilo y kit de vacunacion

Info

Publication number
AR018135A1
AR018135A1 ARP990100873A ARP990100873A AR018135A1 AR 018135 A1 AR018135 A1 AR 018135A1 AR P990100873 A ARP990100873 A AR P990100873A AR P990100873 A ARP990100873 A AR P990100873A AR 018135 A1 AR018135 A1 AR 018135A1
Authority
AR
Argentina
Prior art keywords
acrylic
maleic
copyliments
alquenile
hydroid
Prior art date
Application number
ARP990100873A
Other languages
English (en)
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Sas filed Critical Merial Sas
Publication of AR018135A1 publication Critical patent/AR018135A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La vacuna viva recombinante comprende un vector viral que incorpora y expresa in vivo una secuencia nucleotídica heterologa, preferentemente un gen de unagente patogeno, y por lo menos un compuesto adyuvante elegido entre los polímeros acrílico o metacrílico y los copolímeros de anhídrido maleico y de derivadoalquenilo. Se trata particularmente de un polímero del ácido acrílico o metacrílico reticulado por un éter polialquenílico de azucar o de polialcohol(carbomero), en particular reticulado por una alilpentaeritrita. También se puede tratar de un copolimero de anhídrido maleico y de etileno reticulado, porejemplo por éter divinílico.
ARP990100873A 1998-03-03 1999-03-02 Vacuna viva recombinante, utilizacion de un compuesto elegido entre los polimeros del acido acrilico o metacrilico y los copolimeros de ahidrido maleico yde derivado alquenilo y kit de vacunacion AR018135A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9802800A FR2775601B1 (fr) 1998-03-03 1998-03-03 Vaccins vivants recombines et adjuves

Publications (1)

Publication Number Publication Date
AR018135A1 true AR018135A1 (es) 2001-10-31

Family

ID=9523775

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100873A AR018135A1 (es) 1998-03-03 1999-03-02 Vacuna viva recombinante, utilizacion de un compuesto elegido entre los polimeros del acido acrilico o metacrilico y los copolimeros de ahidrido maleico yde derivado alquenilo y kit de vacunacion

Country Status (22)

Country Link
US (2) US6713068B1 (es)
EP (1) EP1058558B1 (es)
JP (1) JP2002505300A (es)
KR (1) KR20010041507A (es)
CN (2) CN1263511C (es)
AR (1) AR018135A1 (es)
AT (1) ATE287728T1 (es)
AU (1) AU762479B2 (es)
BR (1) BR9908496A (es)
CA (1) CA2321903C (es)
DE (1) DE69923434T2 (es)
DK (1) DK1058558T3 (es)
ES (1) ES2237931T3 (es)
FR (1) FR2775601B1 (es)
HU (1) HU228431B1 (es)
IL (1) IL137872A0 (es)
NZ (1) NZ506370A (es)
PL (1) PL197405B1 (es)
PT (1) PT1058558E (es)
TW (1) TW592700B (es)
WO (1) WO1999044633A1 (es)
ZA (1) ZA991662B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551598B2 (en) 2000-01-21 2003-04-22 Merial Vaccination against canine herpesvirosis and vaccines therefor
FR2804026B1 (fr) * 2000-01-21 2004-06-11 Merial Sas Vaccination contre l'herpesvirose canine et vaccins
US20150231227A1 (en) * 2000-03-02 2015-08-20 Emory University Compositions and methods for generating an immune response
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
CN1443076A (zh) * 2000-05-24 2003-09-17 梅瑞尔公司 猪生殖和呼吸综合症病毒(prrsv)重组禽痘病毒疫苗
US7627145B2 (en) * 2000-09-06 2009-12-01 Hitachi, Ltd. Personal identification device and method
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US20040037848A1 (en) * 2001-04-06 2004-02-26 Audonnet Jean-Christophe Francis Recombinant vaccine against West Nile Virus
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
KR20070048140A (ko) * 2004-06-15 2007-05-08 더 뉴욕 블러드 센터, 인코포레이티드 온코세르카 볼불러스의 천연 생성물의 항원보강성 및 면역강화 특성
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
JP2009512421A (ja) 2005-08-15 2009-03-26 ヴァクシン インコーポレイテッド 非複製性ベクターワクチン投与による鳥類への免疫方法
US20080241184A1 (en) * 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7425336B2 (en) * 2005-08-25 2008-09-16 Mevial Limited Canine influenza vaccines
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8273361B2 (en) 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
UA100370C2 (uk) 2006-12-11 2012-12-25 Мериал Лимитед Спосіб вакцинації птахів проти salmonella
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
CL2008001806A1 (es) * 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
EP3058954B1 (en) 2007-08-27 2017-03-01 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
ES2552858T3 (es) 2007-10-01 2015-12-02 Longhorn Vaccines And Diagnostics, Llc Recogida de muestras biológicas y sistema de transporte y métodos de uso
GB0805356D0 (en) * 2008-03-25 2008-04-30 Isis Innovation Vaccine adjuvant composition
EP2283035B1 (en) 2008-05-08 2015-07-29 Merial Limited Leishmania vaccine using sand fly salivary immunogen
BRPI0920622B1 (pt) * 2008-10-24 2019-11-12 Merial, Inc. vacina contra o vírus da doença equina africana
LT2437753T (lt) 2009-06-05 2016-12-12 Infectious Disease Research Institute Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos
US20130197612A1 (en) * 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
RS58289B1 (sr) 2011-07-20 2019-03-29 Merial Ltd Rekombinantna vakcina protiv virusa mačje leukemije koja sadrži optimizovani gen omotača virusa mačje leukemije
US10166188B2 (en) 2011-08-12 2019-01-01 Merial, Inc. Method for vacuum-assisted preservation of biologics including vaccines
EP3494989B1 (en) 2012-01-26 2025-07-16 Longhorn Vaccines and Diagnostics, LLC Composite antigenic sequences and vaccines
US11510875B2 (en) 2012-02-07 2022-11-29 Access To Advanced Health Institute Adjuvant formulations comprising TLR4 agonists and methods of using the same
US9567606B2 (en) 2012-02-14 2017-02-14 Merial Inc. Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom
BR112014023414B1 (pt) 2012-03-20 2022-08-30 Boehringer Ingelheim Animal Health USA Inc. Vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos
LT2850431T (lt) 2012-05-16 2018-06-25 Immune Design Corp. Vakcinos, skirtos hsv-2
JP6438396B2 (ja) 2012-08-30 2018-12-12 メリアル インコーポレイテッド 不活化ワクチンを作製するための、ならびに組換えタンパク質をリフォールディング／可溶化させるための高圧デバイスおよび方法
KR102039520B1 (ko) 2013-04-18 2019-11-01 이뮨 디자인 코포레이션 암 치료에 이용하기 위한 gla 단일요법
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
CA2948845C (en) 2014-05-14 2022-05-31 Merial, Inc. Methods for freeze-drying and rehydrating biologics
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
CR20200476A (es) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
US10442607B2 (en) 2015-07-31 2019-10-15 Philip Morris Products S.A. Creased blank for forming a container with round or beveled corners
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
HUE059605T2 (hu) 2016-05-16 2022-11-28 Access To Advanced Health Inst TLR agonista tartalmú készítmény és használati eljárások
JP7140684B2 (ja) 2016-06-01 2022-09-21 アクセス ツー アドバンスト ヘルス インスティチュート サイジング剤含有ナノアラム粒子
HRP20250077T1 (hr) 2016-06-17 2025-03-28 Boehringer Ingelheim Vetmedica Gmbh Nove imunogene formulacije koje sadrže ravne ili razgranate polimerne adjuvante poliakrilne kiseline
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CA3078223A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
CN110846284B (zh) * 2019-11-07 2020-12-29 衡阳师范学院 一种犬细小病毒CPV-HuN1703株及其应用
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
CN111500633B (zh) * 2020-04-07 2022-09-16 军事科学院军事医学研究院军事兽医研究所 基于基因编辑技术的重组金丝雀痘病毒构建方法
AU2021280261A1 (en) 2020-05-26 2023-01-19 Dionis Therapeutics, Inc. Nucleic acid artificial mini-proteome libraries
GB2615470A (en) 2020-10-20 2023-08-09 Longhorn Vaccines & Diagnostics Llc Immunogenic antigens
CN113308441B (zh) * 2021-06-02 2022-05-10 华中农业大学 一株猫疱疹病毒i型病毒株及其应用
EP4426829A1 (en) 2021-11-01 2024-09-11 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
CN117511968B (zh) * 2023-11-06 2024-07-05 军事科学院军事医学研究院军事兽医研究所 表达SARS-CoV-2的S、E和M蛋白的重组金丝雀痘病毒及其构建方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790665A (en) 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
US3651213A (en) 1969-05-29 1972-03-21 Monsanto Co Method for the immunization of a living animal body against viral disease
US3919411A (en) 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US3869546A (en) * 1972-12-22 1975-03-04 Cutter Lab Adjuvant compositions and medicinal mixtures comprising them
US3920811A (en) * 1972-12-22 1975-11-18 Cutter Lab Adjuvant compositions
US4309413A (en) 1979-01-22 1982-01-05 Monsanto Company Method of producing immune response by administering polymeric composition
US4567042A (en) 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
US4920213A (en) * 1985-06-20 1990-04-24 Biotechnology Research Partners, Ltd. Method and compositions useful in preventing equine influenza
JPS62201575A (ja) * 1986-02-27 1987-09-05 Shionogi & Co Ltd 家禽用インフルエンザ生ワクチン
US5731188A (en) * 1986-11-20 1998-03-24 Syntro Corporation Recombinant equine herpesviruses
ES2052685T3 (es) 1987-03-17 1994-07-16 Akzo Nv Metodo para producir un adyuvante libre.
US5843456A (en) * 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
EP0532833A1 (en) * 1991-05-28 1993-03-24 Miles Inc. Vaccine for equine rhinopneumonitis
CA2117303C (en) * 1991-11-29 2000-10-17 Sunil Chada Anti-cancer immunotherapeutic vector constructs
FR2700957B1 (fr) * 1993-01-29 1995-03-03 Seppic Sa Composition de vaccin sous-unitaire recombinant vivant et procédé de préparation.
CN1120310A (zh) 1993-03-11 1996-04-10 塞科雷泰克公司 在粘膜表面转运免疫原的聚合粘膜粘合剂
JPH07170982A (ja) * 1993-09-09 1995-07-11 Nisshin Oil Mills Ltd:The ワクチンおよびその製造方法
SI0968722T1 (sl) * 1994-05-10 2007-10-31 Wyeth Corp Izboljĺ ano, modificirano ĺ˝ivo cepivo proti brsv
US6300118B1 (en) 1995-06-07 2001-10-09 American Home Products Corporation Plasmids comprising a genetically altered feline immunodeficiency virus genome
US5849303A (en) 1995-06-07 1998-12-15 American Home Products Corporation Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
ZA97452B (en) * 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
FR2750865B1 (fr) * 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
FR2751226B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
US6004777A (en) * 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6044777A (en) * 1998-02-09 2000-04-04 Walsh; Michael J. Composite metal safe and method of making

Also Published As

Publication number Publication date
EP1058558B1 (fr) 2005-01-26
ES2237931T3 (es) 2005-08-01
PL197405B1 (pl) 2008-03-31
FR2775601A1 (fr) 1999-09-10
HUP0101207A2 (hu) 2001-08-28
AU3257199A (en) 1999-09-20
AU762479B2 (en) 2003-06-26
ATE287728T1 (de) 2005-02-15
HU228431B1 (en) 2013-03-28
TW592700B (en) 2004-06-21
US20060057163A1 (en) 2006-03-16
NZ506370A (en) 2003-07-25
BR9908496A (pt) 2000-12-05
CN1846786A (zh) 2006-10-18
PT1058558E (pt) 2005-06-30
CN1291899A (zh) 2001-04-18
PL342820A1 (en) 2001-07-02
CA2321903A1 (en) 1999-09-10
KR20010041507A (ko) 2001-05-25
FR2775601B1 (fr) 2001-09-21
EP1058558A1 (fr) 2000-12-13
DE69923434D1 (de) 2005-03-03
DE69923434T2 (de) 2006-01-05
WO1999044633A1 (fr) 1999-09-10
IL137872A0 (en) 2001-10-31
JP2002505300A (ja) 2002-02-19
DK1058558T3 (da) 2005-06-06
HUP0101207A3 (en) 2003-10-28
CA2321903C (en) 2011-05-31
CN1263511C (zh) 2006-07-12
US7507416B2 (en) 2009-03-24
US6713068B1 (en) 2004-03-30
ZA991662B (en) 2000-10-12

Similar Documents

Publication Publication Date Title
AR018135A1 (es) Vacuna viva recombinante, utilizacion de un compuesto elegido entre los polimeros del acido acrilico o metacrilico y los copolimeros de ahidrido maleico yde derivado alquenilo y kit de vacunacion
WO1998017310A3 (en) Polyanionic polymers as adjuvants for mucosal immunization
WO2006031264A3 (en) Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
Gómez-Román et al. An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains
AR003384A1 (es) Dispersiones acuosas de polimeros de vinilo y procedimiento para producirlos.
BR9913419A (pt) Enxertamento de monÈmeros etilenicamente insaturados sobre polìmeros
AR030389A1 (es) Compuesto de beta hidroxi carbamato, polimeros del mismo, composiciones que comprenden el polimero, metodo para producir una composicion acuosa que comprende el polimero y metodo para producir el polimero
AU2394297A (en) Defective viral vaccine particles obtained in vivo or ex vivo
AR030677A1 (es) UN COPOLIMERO DE INJERTO CON CONTENIDO DE FLUOR Y UN PROCEDIMIENTO PARA LA PREPARACIoN DEL MISMO
CU23235A1 (es) POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
EP1179564A4 (en) ANTISTATIC RESIN COMPOSITION
AU4195696A (en) Hepatitis e virus antigens and uses therefor
ATE147782T1 (de) Primaten-lentivirus impfstoffe
GB2376687B (en) Herpes viruses for immune modulation
Streeck Designing optimal HIV-vaccine T-cell responses
WO2001083737A3 (en) Porcine adenovirus type 5 vector and vaccine
MX9704368A (es) Pastillas de detergente.
Sharma et al. Are we there yet? The never-ending quest for an Epstein-Barr virus vaccine
WO2003077859A3 (en) Method of inducing an enhanced immune response against hiv
NO20005482L (no) Rekombinant virus og anvendelser derav samt vaksine som omfatter nevnte virus.
JP5732187B2 (ja) 硬化物の製造方法
WO2003076598A3 (en) Method of inducing an enhanced immune response against hiv
JP5750183B2 (ja) 成形体
ATE330583T1 (de) Haarbehandlungsmittel
AP1561A (en) Use of non-cytolytic retrovirus as vaccines for the treatment of HIV infection.

Legal Events

Date Code Title Description
FC Refusal